The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis

Morris E Currie H. Informed choice: is it achievable? Menopause Int 2011; 17: 115.

Makama M Drukker CA Rutgers EJT , et al. An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®). Eur J Cancer 2017; 75: 5–13.

Collaborative Group on Hormonal Factors for Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. DOI: 10.1016/S0140-6736(19)31709-X.

Chlebowski RT Anderson GL Aragaki AK , et al. Association of menopausal hormone replacement therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomised clinical trials. JAMA 2020; 324: 369–380.

Collaborative Group on Hormonal Factors for Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies. Lancet 1997; 350: 1047–1060.

Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333.

Anderson GL Limacher M Assaf AR , et al; Womens’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712.

Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427.

National Institute for Health and Care Excellence; Menopause; Clinical Guideline – methods, evidence and recommendations (NG23), www.nice.org.uk/guidance/ng23 (2015, accessed January 2020).

Santen RJ Yue W. Cause or prevention of breast cancer with estrogens: analysis from tumour biological data, growth kinetic model and Women’s Health Initiative Study. Climacteric 2019; 22: 3–12.

Shapiro S Farmer RD Stevenson JC , et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, part 4: the Million Women Study. J Fam Plann Reprod Health Care 2012; 38: 102–109.

Gigerenzer G. How innumeracy can be exploited. In: Reckoning with risk. London, UK: Penguin, 2003.

Wang K Li F Chen L Lai YM , et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget 2017; 8: 81109–81124.

The 2017 hormone therapy position statement of the North American Menopause Society. Menopause: J N Am Menopause Soc 2017; 24: 728–753.

Marsden J. NICE guideline – menopause: diagnosis and management. Long-term benefits and risks of HRT (Section 11): breast cancer. J Post Reprod Health 2016; 22: 85–91

Conz L Mota BS Bahamondes L , et al. Acta Obstet Gynecol Scan 2020; 99: 970–982.

Yang Z Hu Y Zhang J , et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrincol 2017; 33: 87–92.

The British Menopause Society consensus statement on the management of women with premature ovarian insufficiency, www.thebms.org.uk (2017, accessed December 2019).

Jaakkolo S Lyytinen H Pukkala E , et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obset Gynecol 2009; 114: 1197–1204.

Crandall CJ Hovey KM Andrews CA , et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 2018; 25: 11–20.

www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland (accessed 9 December 2019).

Brown KF Rumgay H Dunlop C , et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer 2015; 118: 1130–1140.

Manson JE Chlebowski RT Stefanick ML , et al. The Women’s Health Initiative hormone therapy trials: update and overview of health outcomes during intervention and post-stopping phases. JAMA 2013; 310: 1353–1368.

Cheblowski RT Thomas RE Manson JE , et al. Breast cancer after use of estrogen plus progestin and estrogen alone. JAMA 2015; 3: 296–305.

Neuhouser M Aragaki A Prentice R , et al. Overweight, obesity and postmenopausal invasive breast cancer risk. JAMA Oncol 2015; 1: 611–621.

Hamajima N Hirose K Tajima K , et al. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87: 1234–1245.

Watson J Wise L Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007; 63: 843–849.

www.ons.org.uk deathsummarytables2017final-2 (accessed 9 December 2019).

Beral V Peto R Pirie K , et al. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet 2019; 394: 1139.

Yu X Zhou S Wang J , et al. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. Breast Cancer 2017; 24: 643–657.

Manson JE Aragaki AK Rossouw JE , et al.; WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative Randomized Trials. JAMA 2017; 318: 927–938.

Colleoni M Sun Z Price KN , et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016; 34: 927–935.

Holm M Olsen A Yeung SLA , et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG 2019; 126: 55–63.

Sarrel PM Njike VJ Vinante V , et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013; 103: 1583–1588.

Santen RJ Heitjan DF Gompel A , et al. Underlying breast cancer risk and menopausal hormone therapy. J Clin Endocr Metab 2020; 105: dgaa073.

National Institute for Health and Care Excellence; Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164), www.nice.org.uk/guidance/cg164 (2013, accessed December 2019).

Gordhandas S Norquist BM Pennington KP , et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019; 153: 192–200.

National Institute for Health and Care Excellence; Early and locally advanced breast cancer: Diagnosis and treatment. NICE guidelines [NG101], www.nice.org.uk/guidance/ng101 (2018, accessed December 2019).

Swain SM Wilson JW Mamounas EP , et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. JNCI 96; 7: 516–523.

Karlsson E Lindström LS Wilking U , et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010; 28: 1009–1009.

Marsden J Morden J A’Hern R , et al. on behalf of the UK HRT Trial Management Group. Hormone replacement therapy (HRT) is effective in relieving oestrogen deficiency symptoms (ODS) and improves quality of life in breast cancer patients: the UK randomised HRT trial experience. Maturitas 2017; 100: 132.

Kenemans P Bundred NJ Foidart JM , et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–146.